Drug recall · April 24, 2019
Amoxicillin for Oral Suspension USP recall
Why: Subpotent Product: assay results for Amoxicillin were below the specification limits.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in (a) 150 mL bottle (NDC 0093-4150-80) (b) 80 mL bottle (NDC 0093-4150-79), Rx Only, Manufactured in Canada By: Teva Canada Limited Toronto, Canada, M1B2K9, Manufactured For: Teva Pharmaceuticals USA, INC. North Wales, PA 19454.
- Lots / codes
Lots: (a) Lot # 35436769A, exp. date 05/2019; 35438389A, 35438390A, exp. date 01/2020; 35440838A, exp. date 10/2020; (b) 35437491A, 35443574B, exp. date 09/2021
- Quantity
- 171,488 150 mL and 80 mL bottles
- Company
- Teva Pharmaceuticals USA, North Wales, PA
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- April 12, 2019 · Voluntary: Firm initiated
- Classified
- April 18, 2019
- Reported
- April 24, 2019
- Ended
- July 8, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Amoxicillin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.